GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

dusigitumab   Click here for help

GtoPdb Ligand ID: 7749

Synonyms: MEDI-573
Compound class: Antibody
Comment: Dusigitumab is an investigational monoclonal antibody which neutralises circulating insulin-like growth factor (IGF)-I and IGF-2. These growth factors regulate cell growth, survival, differentiation, and transformation. Antibody-mediated ligand neutralisation prevents these growth hormones from activating signalling via both IGF1R and IR-A (insulin receptor isoform A, Uniprot identifier P06213-2, RefSeq protein NP_001073285).
Peptide sequence alignment suggests that dusigitumab is antibody 7-159-1 in patent US7939637 [2].
No information available.
Summary of Clinical Use Click here for help
Dusigitumab (research code MEDI-573) is being assessed in clinical trials as a treatment for advanced/metastatic solid tumours [1], including unresectable/metastatic hepatocellular carcinoma (HCC) and HER-2 negative metastatic breast cancer. Click here to link to ClinicalTrials.gov's list of MEDI-573 registered trials.